Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group.

We performed a phase II study with mitoxantrone in patients with carcinoid tumours, islet cell tumours and medullary carcinomas of the thyroid. Thirty-five eligible patients received mitoxantrone 12 mg m-2 i.v. every 3 weeks. Among 18 previously untreated patients, three responded (17%, 95% CI = 4-4...

Descripción completa

Detalles Bibliográficos
Autores principales: Neijt, J. P., Lacave, A. J., Splinter, T. A., Taal, B. G., Veenhof, C. H., Sahmoud, T., Lips, C. J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033476/
https://www.ncbi.nlm.nih.gov/pubmed/7819024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033476/
https://www.ncbi.nlm.nih.gov/pubmed/7819024

Ejemplares similares